SAMCEP Society consensus on the treatment of upper facial lines with botulinum neurotoxin type A: A tailored approach.
aesthetics
consensus guidelines
crow's feet
glabellar frown lines
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
06
03
2023
received:
15
11
2022
accepted:
29
03
2023
medline:
20
9
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
The safety and efficacy of botulinum neurotoxin type A (BoNTA) treatments are well established, but injection techniques, target muscles, and toxin doses continue to evolve, with each refinement producing improvements in treatment outcomes. The recommendations in this consensus move away from standard templates and illustrate how to tailor treatments to individual patterns and strengths of muscle activity, and patient preferences. Seventeen experts in the fields of plastic surgery, dermatology, ophthalmology, otorhinolaryngology, and neurology convened in 2022 to develop consensus-based recommendations for the use of botulinum toxin A for the treatment of horizontal forehead lines, glabellar frown lines, and crow's feet lines that reflect current clinical practice. The focus was on how to tailor injections to individual patients to optimize treatment outcomes. For each upper face indication, consensus members describe how to perform a dynamic assessment to optimize the dose and injection technique for each patient. A tailored treatment protocol is presented for commonly observed patterns of dynamic lines. Units of Inco are defined and the precise location of injection points, illustrated with the use of anatomical images. This consensus provides up-to-date recommendations on the tailored treatment of upper facial lines based on the latest research and collective clinical experience of the expert injectors. Optimal outcomes require thorough patient evaluation, both at rest and during animation, using both visual and tactile cues; detailed understanding of facial muscular anatomy and how opposing muscles interact; and use of a BoNTA with high precision to target identified zones of excess muscle activity.
Sections du résumé
BACKGROUND
BACKGROUND
The safety and efficacy of botulinum neurotoxin type A (BoNTA) treatments are well established, but injection techniques, target muscles, and toxin doses continue to evolve, with each refinement producing improvements in treatment outcomes. The recommendations in this consensus move away from standard templates and illustrate how to tailor treatments to individual patterns and strengths of muscle activity, and patient preferences.
METHODS
METHODS
Seventeen experts in the fields of plastic surgery, dermatology, ophthalmology, otorhinolaryngology, and neurology convened in 2022 to develop consensus-based recommendations for the use of botulinum toxin A for the treatment of horizontal forehead lines, glabellar frown lines, and crow's feet lines that reflect current clinical practice. The focus was on how to tailor injections to individual patients to optimize treatment outcomes.
RESULTS
RESULTS
For each upper face indication, consensus members describe how to perform a dynamic assessment to optimize the dose and injection technique for each patient. A tailored treatment protocol is presented for commonly observed patterns of dynamic lines. Units of Inco are defined and the precise location of injection points, illustrated with the use of anatomical images.
CONCLUSION
CONCLUSIONS
This consensus provides up-to-date recommendations on the tailored treatment of upper facial lines based on the latest research and collective clinical experience of the expert injectors. Optimal outcomes require thorough patient evaluation, both at rest and during animation, using both visual and tactile cues; detailed understanding of facial muscular anatomy and how opposing muscles interact; and use of a BoNTA with high precision to target identified zones of excess muscle activity.
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Neuromuscular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2692-2704Informations de copyright
© 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
International Society of Aesthetic Plastic Surgery (ISAPS). ISAPS international survey on aesthetic/cosmetic procedures performed in 2019. Available from: https://www.isaps.org/wp-content/uploads/2020/12/Global-Survey-2019.pdf. Accessed Nov 14, 2022.
Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018;11:273-287.
Nestor MS, Arnold D, Fischer DL. The mechanisms of action and use of botulinum neurotoxin type a in aesthetics: key clinical postulates II. J Cosmet Dermatol. 2020;19(11):2785-2804.
Kerscher M, Roll S, Becker A, Wigger-Alberti W. Comparison of the spread of three botulinum toxin type a preparations. Arch Dermatol Res. 2012;304(2):155-161.
Grein S, Mander GJ, Fink K. Stability of botulinum neurotoxin type a, devoid of complexing proteins. Botulinum J. 2011;2(1):49-58.
Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, Maas C, Frevert J. Incobotulinumtoxin A: a highly purified and precisely manufactured botulinum neurotoxin type a. J Drugs Dermatol. 2019;18(1):52-57.
Carr WW, Jain N, Sublett JW. Immunogenicity of botulinum toxin formulations: potential therapeutic implications. Adv Ther. 2021;38(10):5046-5064.
Yutskovskaya Y, Gubanova E, Khrustaleva I, et al. Incobotulinumtoxin A in aesthetics: Russian multidisciplinary expert consensus recommendations. Clin Cosmet Investig Dermatol. 2015;8:297-306.
Freeman M, Sayegh F, Sarosi A, et al. Millennials are interested in botulinum toxin injections for prevention of facial rhytids. Face. 2021;2(1):94-98.
Anido J, Arenas D, Arruabarrena C, et al. Tailored botulinum toxin type a injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone. Clin Cosmet Investig Dermatol. 2017;10:413-421.
de Sanctis PC. One21: a novel, customizable injection protocol for treatment of the forehead with Incobotulinumtoxin A. Clin Cosmet Investig Dermatol. 2020;13:127-136.
Galadari H, Galadari I, Smit R, Prygova I, Redaelli A. Use of abobotulinumtoxin A for cosmetic treatments in the neck, and middle and lower areas of the face: a systematic review. Toxins (Basel). 2021;13(2):169.
Sundaram H, Signorini M, Liew S, et al. Global aesthetics consensus: botulinum toxin type a - evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg. 2016;137(3):518e-529e.
de Maio M, Swift A, Signorini M, Fagien S. Aesthetic leaders in facial aesthetics consensus committee. Facial assessment and injection guide for botulinum toxin and injectable hyaluronic acid fillers: focus on the upper face. Plast Reconstr Surg. 2017;140(2):265e-276e.
Kaminer MS, Cox SE, Fagien S, Kaufman J, Lupo MP, Shamban A. Re-examining the optimal use of neuromodulators and the changing landscape: a consensus panel update. J Drugs Dermatol. 2020;19(4):s5-s15.
Fabi SG, Carruthers J, Joseph J, et al. High-dose neuromodulators: a roundtable on making sense of the data in real-world clinical practice. Aesthet Surg J Open Forum. 2021;3(4):ojab036.
Yoelin SG, Kwolek MS, Block JE. Commentary on botulinum toxin injections: a call for improved accuracy. J Clin Aesthet Dermatol. 2020;13(8):13-14.
Costin BR, Wyszynski PJ, Rubinstein TJ, et al. Frontalis muscle asymmetry and lateral landmarks. Ophthalmic Plast Reconstr Surg. 2016;32(1):65-68.
Jia Z, Lu H, Yang X, et al. Adverse events of botulinum toxin type a in facial rejuvenation: a systematic review and meta-analysis. Aesthetic Plast Surg. 2016;40(5):769-777.
Carey WD. Incorrect reconstitution of incobotulinumtoxin A leads to loss of neurotoxin. J Drugs Dermatol. 2014;13(6):735-738.
Niamtu J III. Neurotoxin waste from drawing product through the vial stopper. J Clin Aesthet Dermatol. 2014;7(6):33-37.
Jost WH, Benecke R, Hauschke D, et al. Clinical and pharmacological properties of incobotulinumtoxin A and its use in neurological disorders. Drug des Devel Ther. 2015;9:1913-1926.
Evidente VG, Fernandez HH, LeDoux MS, et al. A randomized, double-blind study of repeated incobotulinumtoxin A (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna). 2013;120(12):1699-1707.
Truong DD, Gollomp SM, Jankovic J, et al. Sustained efficacy and safety of repeated incobotulinumtoxin A (Xeomin(®)) injections in blepharospasm. J Neural Transm (Vienna). 2013;120(9):1345-1353.
Wissel J. Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - insights from recent studies. Toxicon. 2018;147:100-106.
Bocouture 100 units-summary of product characteristics (SmPC)-(emc). https://www.medicines.org.uk/emc/product/7418/smpc#gref. Accessed September 4, 2022
Coleman WP 3rd, Sattler G, Weissenberger P, Hast MA, Hanschmann A. Safety of Incobotulinumtoxin A in the treatment of facial lines: results from a pooled analysis of randomized, prospective, controlled clinical studies. Dermatol Surg. 2017;43(Suppl 3):S293-S303.
Fischer T, Sattler G, Prager W, et al. Safety, tolerability, and efficacy of repeat-dose injections of Incobotulinumtoxin A in the treatment of upper facial lines: results from a prospective, open-label, phase III study. J Drugs Dermatol. 2020;19(5):461-469.
Abramo AC, Do Amaral TP, Lessio BP, De Lima GA. Anatomy of forehead, glabellar, nasal and orbital muscles, and their correlation with distinctive patterns of skin lines on the upper third of the face: reviewing concepts. Aesthetic Plast Surg. 2016;40(6):962-971.
de Sanctis PC, Bussamara Pinheiro MV, Figueiredo V, Guerra R. Aesthetic one21 technique for injecting Incobotulinumtoxin A into the forehead: initial experience with 86 patients. J Drugs Dermatol. 2021a;20(1):31-37.
Hwang K, Lee JH, Lim HJ. Anatomy of the corrugator muscle. J Craniofac Surg. 2017;28(2):524-527.
Lee HJ, Lee KW, Tansatit T, Kim HJ. Three-dimensional territory and depth of the corrugator supercilii: application to botulinum neurotoxin injection. Clin Anat. 2020;33:795-803.
de Almeida AR, da Costa Marques ER, Banegas R, Kadunc BV. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment. Dermatol Surg. 2012;38(9):1506-1515.
Redaelli A, Saromytskaya A, Rowland PC. International expert consensus on the use of AboBotulinum toxin a (AboTA) for facial rejuvenation and primary hyperhidrosis. CosMed. 2017;3(2):70-80.
Prager W. Differential characteristics of incobotulinumtoxin A and its use in the management of glabellar frown lines. Clin Pharmacol. 2013;5:39-52.
de Sanctis PC, Pinheiro MVB, Ventura Ferreira K, de Barros J, Nunes G, Miot HA. The One21 technique: an individualized treatment for glabellar lines based on clinical and anatomical landmarks. Clin Cosmet Investig Dermatol. 2021b;14:97-105.
Sarfati E, Esposito-Valat F, Nefzaoui C. Ptosis traités par injection de toxine botulique: une série de 31 patients. J Méd Chirurgie Dermatol. 2020;199-217.
Lee JY, Kim YK, Seo JY, et al. Loss of elastic fibers causes skin wrinkles in sun-damaged human skin. J Dermatol Sci. 2008;50(2):99-107.
Kane MA, Cox SE, Jones D, Lei X, Gallagher CJ. Heterogeneity of crow's feet line patterns in clinical trial subjects. Dermatol Surg. 2015;41(4):447-456.
Kerscher M, Rzany B, Prager W, Turnbull C, Trevidic P, Inglefield C. Efficacy and safety of Incobotulinumtoxin A in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase III study. Dermatol Surg. 2015;41(10):1149-1157.
Prager W, Nogueira Teixeira D, Leventhal PS. Incobotulinumtoxin A for aesthetic indications: a systematic review of prospective comparative trials. Dermatol Surg. 2017;43(7):959-966.
Trevidic P, Connolly SA, Biwer B, et al. Incobotulinumtoxin A is an effective and well-tolerated treatment for upper facial lines: results from an open-label extension period of a phase III study. Dermatol Surg. 2017;43(Suppl 3):S285-S292.
Pavicic T, Prager W, Klöppel M, Ravichandran S, Galatoire O. Incobotulinumtoxin A use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study. Clin Cosmet Investig Dermatol. 2015;8:135-142.
White L, Tanzi EL, Alster TS. Improving patient retention after botulinum toxin type a treatment. Dermatol Surg. 2006;32(2):212-215